ERBB2 and neoplasm: Although several HER2-targeted treatments are available for patients with early and advanced HER2+ BCs (4) and although their use in the clinical setting has significantly improved patient outcomes, there remains considerable room for optimizing treatment strategies (5) for example by considering individual other than tumor characteristics (e.g., microbiota composition).